-
Add just-published research to your counseling on Depo-Provera (depot medroxyprogesterone acetate or DMPA): Use of the injectable contraceptive is strongly associated with bone density loss; however bone loss appears to be largely reversible once the injections are stopped.1
-
When reviewing birth control options with a teen-age female patient, she tells you that she doesnt want to use the Pill because it will make her gain weight. What do you tell her?
-
In discussing condom use, your college-age male patient tells you that he uses protection on a regular basis. But is he using condoms correctly?
-
As 2002 comes to a close, get ready to add a new lower-dose version of a popular oral contraceptive (OC) to your list of pills, and look to the upcoming 2003 introduction of a generic form of a long-time Pill favorite.
-
This summer, the Bush administration officially announced it was cutting off all U.S. support for the United Nations Population Fund (UNFPA), the largest multilateral population assistance agency in the world.
-
Take a look at your paycheck; chances are if you are in the family planning field, it shows a slight increase from 2001.
-
Expanding upon their earlier study that demonstrated that spouses of hypertensive patients are more likely to be hypertensive themselves, these British researchers studied couples to determine whether other illnesses exhibited the same association.
-
Among patients being evaluated for chronic cough, women are more sensitive than men to inhalation of tussive agents.
-
GlaxoSmithKline is expected to launch a new drug for benign prostatic hypertrophy in December. Dutasteride is a 5 alpha-reductase inhibitor, which was previously approved in November 2001 but not launched.
-
Debate over the cardiovascular effects of COX-2 inhibitors has raged
for more than a year since a special communication was published in
JAMA last August suggesting an increase in cardiovascular events with
rofecoxib (Vioxx). Now a large retrospect, the cohort study from the
Tennessee Medicaid program seems to confirm the prothrombotic effects
of rofecoxib, at least in high dose.
